Comparing reactions to COVID-19 and influenza vaccinations: data from patient self-
reporting, smartwatches and electronic nearth records
Matan Yechezkel, MS <sup>1</sup> , Gary Qian, MS <sup>2</sup> , Yosi Levi, MS <sup>1</sup> , Nadav Davidovitch, PhD <sup>3</sup> , Erez
Shmueli, PhD <sup>1,4*</sup> , Dan Yamin, PhD <sup>1,5*</sup> , Margaret L. Brandeau, PhD <sup>2*</sup>
June 23, 2023
<sup>1</sup> Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel
<sup>2</sup> Department of Management Science and Engineering, Stanford University, Stanford,
California, United States of America
<sup>3</sup> School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev,
Beersheva 84105, Israel
<sup>4</sup> MIT Media Lab, Cambridge, MA, USA.
<sup>5</sup> Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.
*Contributed equally
Address correspondence to: Matan Yechezkel, matany92@gmail.com
<b>Keywords:</b> COVID-19 vaccine, COVID-19 booster vaccine, BNT162b2, adverse effects, wearable sensors, influenza vaccine, seasonal influenza, vaccine reactions

# 28 SUMMARY

Background Public reluctance to receive COVID-19 vaccination is due in large part to safety concerns. We compare the safety profile of the BNT162b2 COVID-19 booster vaccine to that of the seasonal influenza vaccine, which has been administered for decades with a solid safety record and a high level of public acceptance.

33 Methods We study a prospective cohort of 5,079 participants in Israel (the PerMed study) and a 34 retrospective cohort of 250,000 members of Maccabi Healthcare Services. We examine reactions 35 to BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 booster vaccinations and to influenza 36 vaccination. All prospective cohort participants wore a Garmin Vivosmart 4 smartwatch and 37 completed a daily questionnaire via smartphone. For the prospective cohort, we compare pre-38 vaccination (baseline) and post-vaccination smartwatch heart rate data and a stress measure 39 based on heart rate variability, and we examine symptom severity from patient self-reports. For 40 the retrospective cohort, we examine electronic health records (EHRs) for the existence of 28 41 potential adverse events during the 28-day period before and after each vaccination.

42 Findings In the prospective cohort, 1,905 participants received COVID-19 vaccination; 899 43 received influenza vaccination. Focusing on those who received both vaccines vielded a total of 689 participants in the prospective cohort and 31,297 members in the retrospective 44 45 cohort. *Questionnaire analysis*: For the COVID-19 vaccine, 39.7% [95% CI 36.4%-42.9%] of 46 individuals reported no systemic reaction vs. 66.9% [95% CI 63.4%-70.3%] for the influenza vaccine. Individuals reporting a more severe reaction after influenza vaccination tended to 47 likewise report a more severe reaction after COVID-19 vaccination (r=0.185, p<0.001). 48 49 Smartwatch analysis: A statistically significant increase in heart rate and stress measure occurred 50 during the first 3 days after COVID-19 vaccination, peaking 22 hours after vaccination with a

51 mean increase of 4.48 (95% CI 3.94–5.01) beats per minute and 9.34 (95% CI 8.31–10.37) units 52 in the stress measure compared to baseline. For influenza vaccination, we observed no changes 53 in heart rate or stress measures. In paired analysis, the increase in both heart rate and stress 54 measure for each participant was higher (p-value < 0.001) for COVID-19 vaccination than for influenza vaccination in the first 2 days after vaccination. On the second day after vaccination, 55 participants had 1.5 (95% CI 0.68–2.20) more heartbeats per minute and 3.8 (95% CI 2.27–5.22) 56 57 units higher stress measure, compared to their baseline. These differences disappeared by the 58 third day after vaccination. EHR analysis: We found no elevated risk of non-COVID-19 or -59 influenza hospitalization following either vaccine. COVID-19 vaccination was not associated 60 with an increased risk of any of the adverse events examined. Influenza vaccination was associated with an increased risk of Bell's palsy (1.3 [95% CI 0.3-2.6] additional events per 61 62 10,000 people).

Interpretation The more pronounced side effects after COVID-19 vaccination compared to influenza vaccination may explain the greater concern regarding COVID-19 vaccines. Nevertheless, our findings support the safety profile of both vaccines, as the reported side effects and physiological reactions measured by the smartwatches faded shortly after inoculation, and no substantial increase in adverse events was detected in the retrospective cohort.

Funding This work was supported by the European Research Council, project #949850, and a
Koret Foundation gift for Smart Cities and Digital Living.

70

71

## 72 **RESEARCH IN CONTEXT**

#### 73 Evidence before this study

74 The unprecedented global impact of COVID-19 led to the rapid development and deployment of 75 vaccines against the virus, including vaccines using novel mRNA technology. Despite the 76 promising effectiveness of mRNA vaccines in preventing severe outcomes of COVID-19, 77 concerns have been raised regarding the safety profile of these new vaccines. These concerns led 78 to a notable global public reluctance to become vaccinated. By contrast, the seasonal influenza 79 vaccine has been administered for decades with a well-established safety record and a high level 80 of public acceptance. We searched Google Scholar, PubMed, and preprint services (including 81 medRxiv, bioRrxiv, and SSRN) for studies comparing the safety profile of the two vaccines 82 between March 1, 2023 (our study's launch) and May 30, 2023, with no language restrictions, 83 using the terms "safety of" AND ("COVID-19" OR "SARS-CoV-2") AND ("vaccine" OR 84 "BNT162b2 (Pfizer-BioNTech) mRNA vaccine") AND "compared to" AND ("Influenza" OR "seasonal influenza" OR "flu") AND "vaccine". We found a study that compared the safety 85 86 profile of the mRNA COVID-19 vaccine among 18,755 recipients with 27,895 recipients of the 87 seasonal influenza vaccine using the WHO international database. The authors found a different 88 safety pattern between the two vaccines with more systematic reactions following inoculation of 89 the COVID-19 vaccine. Additionally, COVID-19 vaccines were associated with a higher risk of 90 cardiovascular adverse events, while the influenza vaccine was associated with a higher risk of neurological adverse events. The remaining studies identified in our search compared the 91 92 simultaneous administration of both vaccines to the administration of only COVID-19 vaccines. 93 None of the studies conducted a paired analysis that compared reactions post-influenza 94 vaccination and post-COVID-19 vaccination for the same individual; none examined the extent

95 of physiological reaction (in terms of heart rate and heart rate variability) following the 96 administration of COVID-19 or seasonal influenza vaccines; and none examined a cohort of 97 individuals with data from before and after vaccination episodes or presented a comprehensive 98 analysis to address concerns regarding the existence of potential rare adverse events following 99 vaccination.

#### 100 Added value of this study

101 We studied a prospective cohort of 5,079 participants in Israel (the PerMed study) from October 102 31, 2020 to September 30, 2022 and a retrospective cohort of 250,000 members of Maccabi 103 Healthcare Services from July 31, 2021 and March 1, 2023. We examined reactions to 104 BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccination (third or fourth shot) and to 105 influenza vaccination. We compared the extent of reactions at the individual level, among individuals who received both vaccines separately. While the self-reported data and the 106 107 continuous physiological measures from smartwatches revealed a higher rate of reactions 108 following COVID-19 vaccination, these reactions faded soon after inoculation. We found no 109 increase in risk of rare adverse events for either vaccine. We found a weak, albeit significant, 110 correlation in the severity of the symptoms for the two vaccines (r=0.185, p<0.001): individuals 111 who reported a more severe reaction after influenza vaccination tended to likewise report a more 112 severe reaction after COVID-19 vaccination. We found no elevated risk of non-COVID-19 or -113 influenza hospitalization following the administration of either vaccine. COVID-19 vaccination 114 was not associated with increased risk of any of the adverse events examined. Influenza 115 vaccination was associated with an increased risk of Bell's palsy (1.3 [95% CI 0.3-2.6] 116 additional events per 10,000 people).

#### 117 Implications of all the available evidence

118 Our study demonstrates the importance of accounting for continuous and objective surveillance 119 of vaccines in both the clinical trial phase and the post-marketing phase, as it can aid in 120 evaluating the safety profile of clinical trials and reduce vaccine hesitancy. The more pronounced 121 side effects after COVID-19 vaccination compared to influenza vaccination may explain the 122 greater concern regarding COVID-19 vaccines. Nevertheless, our findings support the safety 123 profile of both vaccines, as the reported side effects and physiological reactions measured by the 124 smartwatches faded shortly after inoculation, and no substantial increase in adverse events was 125 detected in the retrospective cohort.

# 127 **INTRODUCTION**

The unprecedented global impact of COVID-19 led to the rapid development and deployment of vaccines against the virus, including vaccines using novel mRNA technology. However, despite the promising safety profile and effectiveness of mRNA vaccines in preventing severe outcomes of COVID-19, there has been a notable global public reluctance to be vaccinated.<sup>1, 2</sup> For example, in the United States nearly 20% of the population has received no COVID-19 vaccine doses.<sup>3</sup> A key reason for COVID-19 vaccine hesitancy is concerns about the safety of the vaccine.<sup>4, 5</sup>

One strategy to address such concerns is by comparing the side effects of the mRNA vaccines to the side effects of the seasonal influenza vaccine, which has been administered for decades with a solid safety record and a high level of public acceptance. Hundreds of millions of vaccines for seasonal influenza and COVID-19 have been administered to date<sup>6, 7</sup> but information comparing the safety of these vaccines is limited.

Currently, information on vaccine side effects is primarily collected through selfreporting methods, but these methods may be subject to bias and underreporting. To address this issue and provide a more comprehensive assessment of vaccine safety, extensive, continuous, and detailed monitoring of physiological changes in vaccinated individuals is necessary. Wearable devices, such as smartwatches, offer a promising solution. They enable continuous, detailed monitoring of physiological changes in vaccinated individuals, which can help identify vaccine-associated adverse events more effectively than self-reporting alone.

Wearable sensors have been shown to detect subtle medical conditions, such as atrial fibrillation, based on irregular heartbeats.<sup>8</sup> Several studies have shown that heart metrics, including heart rate, heart rate variability, and resting heart rate, can indicate COVID-19

150 infection in the pre-symptomatic stage and thus can be used for real-time detection.<sup>9-11</sup> These 151 heart metrics have been previously reported to correlate with subjective symptoms after the 152 COVID-19 vaccine.<sup>12, 13</sup> In the context of COVID-19 vaccination, a number of studies using 153 wearables have observed short-term changes in heart metrics following vaccination, even when 154 such changes were not apparent to patients when self-reporting effects of vaccination.<sup>14-18</sup>

155 In this study, our goal is to evaluate the safety of mRNA COVID-19 booster vaccines by 156 comparing their side effects with those of seasonal influenza vaccines, using self-reported data, 157 physiological measurements from Garmin Vivosmart 4 smartwatches, and information from 158 electronic health records (EHRs). We examined the short-term effects (lasting up to 42 days) of 159 the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 booster vaccine and contrasted it with the 160 seasonal influenza vaccine, by analyzing data from a prospective cohort of 5,079 participants in an observational trial, as well as a retrospective cohort of 250,000 randomly selected members 161 162 from Maccabi Healthcare Services, Israel's second-largest healthcare provider (which serves 163 about 25% of the population).

#### 164 **METHODS**

## 165 **Cohorts**

**Prospective cohort** We studied a cohort of 5,079 participants from a prospective observational trial of individuals in the PerMed study<sup>14-17, 19</sup> who received a third or fourth BNT162b2 mRNA COVID-19 vaccine and a seasonal influenza vaccine between July 31, 2021 and September 30, 2022 (Figure S2A, appendix p 13; see study protocol, appendix pp. 2-12) Participants filled out a daily questionnaire about clinical symptoms and wore a smartwatch that measured, among other factors, heart rate and heart rate variability-based stress.

Upon enrollment in the study, we gathered information on the participants' sex, age, and pre-existing clinical risk factors. These underlying medical conditions included diabetes, hypertension, heart disease, chronic pulmonary conditions, weakened immune system, cancer, kidney failure, and a body mass index (BMI) greater than 30 (BMI is determined by dividing a person's weight in kilograms by the square of their height in meters).

177 We paired observations so that we could compare vaccine reactions in each individual. 178 Among the 5,079 participants in the prospective cohort, a total of 4,334 COVID-19 vaccine 179 doses and 2,639 influenza vaccine doses were administered. For both types of vaccines, we had 180 hourly smartwatch data on heart rate and a Garmin-computed stress measure based on heart rate 181 variability (heart rate: 1,877 COVID-19 vaccine doses, 901 influenza vaccine doses; stress 182 measure: 1,845 COVID-19 vaccine doses, 878 influenza vaccine doses) (Table S2 appendix 183 p14). From these observations we extracted paired vaccine observations; these are observations 184 for individuals who received both the COVID-19 vaccine (first or second booster) and at least 185 one influenza vaccine.

**Retrospective cohort** For the retrospective cohort, we examined anonymized EHRs of 250,000 randomly selected members of Maccabi Healthcare Services (Figure S2B, appendix p 13; see study protocol, appendix pp. 2-12). Eligible members were individuals 18 years and older who received both a third or fourth BNT162b2 mRNA COVID-19 vaccine and a seasonal influenza vaccine between July 31, 2021 and March 1, 2023. Individuals who were not members of Maccabi Healthcare Services throughout the entire study period were excluded.

192 Study Design

**Prospective cohort** For the prospective cohort, participants were asked to complete a
 daily survey via the PerMed mobile application.<sup>19</sup> This survey compiled self-reported clinical

195 symptoms from participants, using a predefined list of reactions observed in the BNT162b2 196 mRNA COVID-19 vaccine trial <sup>20</sup>, while also allowing participants to freely report any 197 additional symptoms they experienced. The survey was crafted based on potential symptoms that 198 may follow infections with infectious diseases and respiratory illnesses, drawing on the 199 International Classification of Diseases, Ninth Revision, and Clinical Modification (ICD-9) 200 codes related to influenza, influenza-like illnesses, acute respiratory infections, RSV (respiratory 201 syncytial virus), group A streptococcus, and COVID-19.

Throughout the study, from the moment they were recruited until the end, participants wore a Garmin Vivosmart 4 smartwatch. The smartwatch data was used to estimate the effects of vaccination on physiological measures such as heart rate and stress levels. Stress levels, computed by Garmin, range from 1 to 100 and are classified into four categories: resting (1-25), low (26-50), medium (51-75), and high (76-100).<sup>21</sup> A higher stress level correlates with lower heart rate variability.<sup>22, 23</sup> Heart rate data (beats per minute) was collected in intervals of 15 seconds while stress measurements were documented every three minutes.

Further information regarding the recruitment procedure, choice of smartwatch data analyzed, data collection architecture, and PerMed dashboard is provided elsewhere.<sup>16</sup>

Retrospective cohort For the retrospective cohort, we examined anonymized EHRs of the patients. These records are automatically collected from various clinics and medical facilities nationwide and updated monthly in Maccabi Healthcare Services databases. The data is coded, anonymized, viewed, stored, and processed within the research room of the Maccabi Healthcare Services. Maccabi Healthcare Services uses the ICD-9 classification with procedures coded using Current Procedural Terminology codes. We obtained demographic details for each patient, along with diagnoses linked to 28 possible adverse events, as specified by ICD-9 codes.

# 218 **Outcomes and Statistical Analysis**

Prospective cohort Though the majority of participants only filled out the survey once daily, if there were multiple entries by a single participant within a day, only the final entry was considered. Since questionnaires cannot be updated after submission, participants were instructed to submit a new response in case of filing errors; we assumed that the last entry provided a more accurate representation of the participant's entire day.

224 We defined a "baseline period" for each participant using their data (self-reported 225 questionnaire and smartwatch) 7 days prior to vaccination. A participant's "baseline" refers to 226 the last questionnaire they submitted during the baseline period and smartwatch data for the 227 entire baseline period. If a symptom was reported following the vaccination and was not noted 228 during the baseline period, we interpreted this to be a side effect of the vaccine. Participants who 229 did not complete the questionnaire during the baseline period were omitted from our analysis 230 because we could not determine whether their symptoms existed prior to vaccination. We 231 compared the baseline period to 7 and 14 days after vaccination inclusive of vaccination day 232 ("post-vaccination" period), for discrete and continuous metrics, respectively. Since the U.S. 233 Centers for Disease Control and Prevention (CDC) advises that vaccine side effects typically disappear after a few days, our analysis concentrates on the first 72 hours post-vaccination.<sup>24</sup> 234

We included participants who (1) submitted the questionnaire at least once during the baseline period, (2) completed the questionnaire at least once within 72 hours after vaccination, (3) provided wearable device measurements during the same day-of-week and time-of-day during their post-vaccination and baseline periods, and (4) received both the seasonal influenza and COVID-19 vaccine.

We excluded participants who provided data for only one day (either during the baseline or post-vaccination periods), with an exception if the participant provided data for the same hours-of-day and days-of-week during the baseline and post-vaccination periods.

We differentiated participants based on their self-reported intensity of symptoms as recorded in a questionnaire during the 72 hours following each vaccination. Participants were grouped into "No Reaction," "Mild Reaction," or "Severe Reaction" categories, based on their most severe symptom reported in the 72 hours following each vaccination. Consequently, if a participant experienced a single severe symptom for a day, and mild symptoms for the remaining three days post-vaccination, they were designated as having a severe reaction. The severity categorization could vary for participants after each administered vaccine dose.

In alignment with the  $CDC^{25}$  and the Pfizer clinical trial<sup>20</sup>, we categorized symptoms as follows:

Mild symptoms: abdominal pain, feeling hot, back or neck pain, feeling cold, muscle
 pain, weakness, headache, dizziness, vomiting, sore throat, diarrhea, cough, leg pain, ear
 pain, loss of taste and smell, swelling of the lymph nodes, fast heartbeat, and
 hypertension;

• Severe symptoms: chest pain, dyspnea (shortness of breath), fever, confusion, and chills.

For participants who reported feeling hot and recorded their temperature, we divided them into two categories: above 38.9° C (fever) or below 38.9° C (feeling hot); in cases where the participant did not record their temperature, we assumed it to be below 38.9° C.

From the questionnaire data, we computed the proportion and corresponding 95% confidence interval (CI) of participants who reported experiencing each side effect in the postvaccination period. The 95% CI for each side effect was calculated using a binomial distribution

Binom(*n*,*p*), where *p* = the proportion of participants reporting the symptom, and *n* = number of participants eligible to be included in the self-reported questionnaire analysis. In cases where participants received more than one dose of the COVID-19 or the seasonal influenza vaccine during the study period, and were eligible to be included for both inoculations, each self-reported event (i.e., specific symptoms or no symptoms) was considered as  $\frac{1}{number of vaccine episodes}$  event

to avoid over counting.

269 For the continuous Garmin smartwatch data, we compared measurements from the post-270 vaccination period to the corresponding day-of-week and hour-of-day measurement from the 271 baseline period at the individual level. For example, we compare a participant's Wednesday 272 average 9 am heart rate with their previous Wednesday 9 am heart rate. If these data were not 273 recorded (e.g., if a participant did not wear the smartwatch in the same period before and after 274 vaccination), we excluded the participant from this analysis. Then, we aggregated each hour's 275 differences divided by all participants to calculate a mean difference and the associated 95% CI. 276 We present this analysis starting a week before and after vaccination. In cases where participants 277 received more than one dose of the COVID-19 or the seasonal influenza vaccines during the 278 study period, and were eligible to be included for both inoculations, we calculated the average 279 differences over all inoculations.

We also compared the difference of physiological changes between COVID-19 vaccination and seasonal influenza vaccination among individuals who received both vaccines. For each participant, we first calculated the daily mean changes in heart rate between the postvaccination period and the baseline period. We did this separately for the mRNA COVID-19 booster vaccine and the seasonal influenza vaccine. Then we calculated the difference between

these two mean values for each participant and each of the 7 days after inoculation. This is equivalent to a two-sided Welch's t-test, which does not assume equal population variance.

**Retrospective cohort** For each individual in the retrospective cohort who received both vaccines, we noted the existence in the EHR of 28 potential adverse events (Table S1, appendix pp 10-11) during the 28-day period before and after each vaccination. This set of adverse events was composed based on a previous large-scale study that examined the safety of the first and second (primary series) COVID-19 vaccine dose.<sup>26</sup>

292 We calculated the number of adverse events shown in patients' EHRs before and after each vaccine. Consistent with a previous study<sup>27</sup>, we chose a time interval of 28 days to evaluate 293 294 the potential short-term effects of each of the vaccines separately. Similar to large cohort studies.<sup>16, 28</sup> we evaluated the risk differences using a self-as-control method that compared 295 296 adverse events in the same patient in two periods: a baseline period of 28 days (from 35-8 days 297 before vaccination) and a post-vaccination period of 28 days (0-27 days after vaccination). We 298 used a 7-day buffer period between the baseline and post-vaccination periods in accordance with the guidelines of the Israeli Ministry of Health,<sup>29</sup> which recommend that an individual should not 299 300 receive inoculation if suffering from any apparent infection with severe symptoms, including a 301 fever higher than 38°C. This 7-day buffer period was also consistent with the assumption made 302 by a large-scale safety study in which non-vaccinated individuals were not eligible to serve as controls if the person experienced any health event in the week before the follow-up period.<sup>26</sup> 303

During outpatient visits in Maccabi's clinics, past diagnoses also appear as part of the current visit's diagnoses. Thus, in line with the previous study, for each adverse event we omitted individuals who were previously diagnosed with the same event in the year prior to the baseline period.<sup>26</sup>

medRxiv preprint doi: https://doi.org/10.1101/2023.06.28.23292007; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

308 We conducted a pairwise comparison for each individual, calculating the risk difference between pre- and post-vaccination values, which we denote  $Y_{diff}^{i,j}$  for person *i* and event *j*. If an 309 310 adverse event was recorded in the individual's medical records in the post-vaccination period 311 (i.e., 0-27 days post-vaccination) but not in the pre-vaccination period (35-8 days pre-312 vaccination), then the event is potentially associated with the vaccine or a random event, and we set  $Y_{diff}^{i,j} = 1$ . If the converse was true and an adverse event appeared before vaccination but not 313 after vaccination, the event is potentially a random event, and we set  $Y_{diff}^{i,j} = -1$ . If a specific 314 event was reported in both the pre- and post-vaccination periods, we assumed the event is not 315 associated with the vaccine and we set  $Y_{diff}^{i,j} = 0$ , and thus the individual was excluded from the 316 317 analysis of event *j*. If an individual was found to be positive for COVID-19 during the post-318 vaccination period, we compared only the events recorded in the period between the inoculation 319 and the recorded time of death and matched this period with the same time interval in the 320 baseline period.

The risk difference for event j is the mean value of  $\overline{Y}_{diff}^{,j}$  calculated over all vaccinated 321 322 individuals. This approach mirrors the standard estimation of risk differences in exposed and unexposed groups<sup>30</sup>, while taking into account the paired nature of the samples. To calculate the 323 324 95% CI for the difference without imposing any unknown distribution, we applied a non-325 parametric percentile bootstrap method with 10,000 repetitions, similar to previous safety studies<sup>26, 28</sup>. In case an individual received more than one inoculation of COVID-19 vaccine or 326 327 more than one inoculation of the seasonal influenza vaccine, for each repetition we chose 328 randomly one of inoculations for each vaccine type.

329 Ethical Approval

330 The prospective study was approved by MHS' Helsinki institutional review board, 331 protocol number 0122-20-MHS. All participants gave written informed consent to participate in 332 the study and were advised both orally and in writing of the nature of the study. This study is part 333 of a larger study (an observational clinical trial funded by a European Research Council grant) 334 and is in accordance with the European Union General Data Protection Regulation: a cohort of 335 5,000 participants are recruited, download a dedicated mobile application, receive smartwatches, 336 grant access to their medical records, and are followed for two years. Since the retrospective data 337 was pseudonymized, the Helsinki institutional review board approved the use of this cohort data 338 without requiring specific consent from Maccabi Healthcare Services members (protocol number 339 0122-20-MHS).

**Role of the Funding Source** 

341 The sponsor of the study had no role in the study's design, data collection, data analysis342 and data interpretation, or in the writing of the report.

## 343 **RESULTS**

#### **344 Prospective Cohort**

#### 345 **Cohort characteristics**

A total of 2115 participants received either the COVID-19 vaccine or the influenza vaccine during the study period (Table 1). Among these participants, 1905 received the COVID-19 vaccine, while 899 received the influenza vaccine. In the paired sample of 689 participants receiving both vaccines, 355 (51.5%) were female, and age ranged from 20-85 years, with a median of 58. This is significantly higher than the median age in Israel, which is 30.5 years.<sup>31</sup> Among the 689 participants, 357 (51.8%) reported that they had an underlying medical condition and 177 (25.7%) had a BMI of 30 or greater.

353 When we paired observations for individuals who received both COVID-19 and 354 influenza vaccines, we obtained 799 paired COVID-19 vaccine doses and 692 paired influenza 355 vaccine doses for heart rate; and 779 paired COVID-19 vaccine doses and 672 paired influenza 356 vaccine doses for the stress measure (Table S2, appendix p 14). These numbers are 357 representative of 577 and 544 individuals with heart rate and stress data, respectively, who 358 received both vaccines. Similarly, we had 881 paired daily self-reports on symptoms for 7 days 359 pre- and post-COVID-19 vaccination and 727 pre- and post-influenza vaccination paired self-360 reports, corresponding to 621 individuals.

Questionnaire analysis For the COVID-19 vaccine, 39·7% [95% CI 36·4%–42·9%] of individuals reported no systemic reaction; for the influenza vaccine, this fraction was 66·9% [95% CI 63·4%–70·3%] (Figure 1). The most common reactions reported for the COVID-19 vaccine were weakness (16·1% [95% CI 13·6%–18·5%] of vaccinated individuals), headache (13·1% [95% CI 10·9%–15·3%]), muscle pain (12·1% [95% CI 10·0%–14·3%]), fever (7·0%

[95% CI 5·3%-8·7%]), and chills (5·7% [95% CI 4·2%-7·3%]). The most common reactions
reported for the influenza vaccine were weakness (7·3% [95% CI 5·5%-9·2%]), headache (5·3%
[95% CI 3·7%-7·0%]), muscle pain (3·6% [95% CI 2·3%-5·1%]), feeling cold (3·5% [95% CI
2·2%-5·0%]), and sore throat (3·0% [95% CI 1·8%-4·3%]).

370 We compared severity of symptoms for the 621 individuals who received both a COVID-19 and influenza vaccine and who self-reported symptoms for both (Figure S3, appendix p 16). 371 372 Using Spearman's rank correlation test we found a weak, albeit significant, correlation in the 373 severity of the symptoms for the two vaccines (r=0.185, p<0.001). Specifically, individuals who 374 reported a more severe reaction after influenza vaccination tended to likewise report a more 375 severe reaction after COVID-19 vaccination. Of the 621 individuals, 278 (44.8%) reported no 376 reaction to either vaccine, 173 (27.8%) reported no reaction to the influenza vaccine and a mild 377 reaction to the COVID-19 vaccine, and 36 (5.8%) reported no reaction to the influenza vaccine 378 and a severe reaction to the COVID-19 vaccine. Similarly, 58 individuals (9.3%) reported a mild 379 reaction to both vaccines, 38 individuals (6.1%) reported a mild reaction to the influenza vaccine 380 and no reaction to the COVID-19 vaccine, and 25 individuals (4.0%) reported a mild reaction to 381 the influenza vaccine and a severe reaction to the COVID-19 vaccine. Only 5 individuals (0.8%) reported a severe reaction to both vaccines. Of the 621 individuals, 321 (54.9%) reported the 382 383 same level of symptom severity for both vaccines, and 259 (41.7%) reported a higher level of 384 symptom severity for the COVID-19 vaccine than for the influenza vaccine. Only 46 individuals 385 (7.4%) reported a lower level of symptom severity for the COVID-19 vaccine than for the 386 influenza vaccine.

Wearables analysis We examined mean pre- and post-vaccination differences in hourly
 heart rate and stress data for participants who received either the COVID-19 or influenza vaccine

(Figure 2). Following the administration of the COVID-19 vaccine, we identified a statistically 389 390 significant increase in heart rate during the first three days compared to the baseline period. This 391 increase peaked 22 hours after vaccination, with a mean difference of 4.48 (95% CI 3.94-5.01) 392 more beats per minute compared to baseline. By the sixth day post-inoculation, heart rate levels 393 returned to baseline. A similar trend was observed for stress data: the increase in stress measure 394 was statistically significant with a peak 22 hours after vaccination and a mean increase of 9.34395 (95% CI 8.31–10.37) units in the stress measure. For influenza vaccination, no statistically 396 significant changes in heart rate or the stress measure were observed.

397 To directly compare effects of the two vaccines we conducted a pairwise comparative 398 analysis in which we examined daily mean changes in heart rate and the stress measure for 399 individuals receiving both vaccines (Figure 3). For each such participant, we calculated the mean 400 change in the indicator (either heart rate or stress) associated with COVID-19 vaccination 401 compared to an individual's baseline levels minus the mean change in the indicator associated 402 with influenza vaccination compared to the individual's baseline. Figure 3 shows that the 403 increase in both heart rate and the stress measure for each participant was higher for COVID-19 404 vaccination than for influenza vaccination in the first two days after vaccination, and that this 405 increase is statistically significant (p-value < 0.001). However, these differences were small: for 406 example, in the second day after vaccination, mean heart rate was 1.5 (95% CI 0.68-2.20) beats 407 per minute higher after COVID-19 vaccination than after influenza vaccination, compared to an 408 individual's baseline, and mean stress was 3.8 (95% CI 2.27-5.22) units higher. Moreover, these 409 differences disappeared by the third day after vaccination: for the third through seventh days 410 after vaccination there were no statistically significant differences in changes in these two 411 indicators for the COVID-19 vaccine compared to the influenza vaccine.

# 412 **Retrospective Cohort**

413 **Cohort characteristics** The retrospective cohort included 31,297 Maccabi members who 414 received both vaccines during the study period. Of these individuals, 16,956 (54·2%) were 415 female (Table 1). Age ranged from 12-103 years, with a median of 59. An underlying medical 416 condition was listed in the medical record for 14,437 (45·8%) individuals, and 5,069 (16·2%) had 417 a BMI of 30 or greater.

418 EHR analysis We found no elevated risk of non-COVID-19 or -influenza 419 hospitalizations following the administration of either vaccine (Table 2). Among the 31,297 420 individuals receiving both vaccines, 37 non-COVID-19 or -influenza hospitalizations occurred in 421 the post-vaccination period compared to 51 in the baseline period for the COVID-19 vaccine 422 and 32 non-COVID-19 or -influenza hospitalizations in the post-vaccination period compared to 423 30 in the baseline period for the influenza vaccine, corresponding to risk differences of -4.5 424 (95% CI: -10·2–1·3) and -0·6 (95% CI: -5·8–4·2) events per 10,000 vaccinated individuals, 425 respectively.

We found no statistically significant increase in risk of the examined adverse events for COVID-19 vaccination (Table 2). Influenza vaccination was associated with an increased risk of Bell's palsy (1.3 [95% CI 0.3-2.6] additional events per 10,000 people), but was not associated with any other increase in risk of the examined adverse events.

#### 430 **DISCUSSION**

Our analyses of data from patient questionnaires and smartwatches (in a prospective
study) and from EHRs (in a retrospective study) comparing side effects of COVID-19 booster
vaccination and seasonal influenza vaccination further support the safety of the first and second
BNT162b2 booster vaccinations in eligible populations. In the patient questionnaires, more

435 individuals reported mild or severe effects after the COVID-19 vaccine than after the influenza 436 vaccine (60.3% vs. 33.1%). We found a weak but significant positive correlation in the severity 437 of the symptoms for the two vaccines. From the smartwatch data we identified a small but 438 statistically significant increase in heart rate and the stress measure in the three days after 439 COVID-19 vaccination, with levels returning to normal within six days after vaccination. For 440 influenza vaccination, no statistically significant changes in these measures were observed. 441 Although our paired analysis of reactions to COVID-19 and influenza vaccination suggested that 442 the differences are significant, they were small and do not indicate lack of safety. Importantly, 443 for the retrospective cohort, our analysis of EHRs – which are based on diagnoses of physicians 444 in clinics and hospitals -identified no significant change in risk of adverse events after either 445 vaccine, except for an elevated risk of Bell's palsy after the influenza vaccine, a rare event. This finding is in line with a recent large-scale study that also found this positive association.<sup>32</sup> 446 447 Despite this finding, the benefits of influenza vaccination in preventing severe outcomes far 448 exceed this risk.

449 At both the aggregate level where we compared average changes in smartwatch measures 450 pre- and post-vaccination for COVID-19 versus influenza vaccination, and at the individual level 451 where we compared each patient's changes in these measures, we found an increase in heart rate: 452 4.48 (95% CI 3.94-5.01) beats per minute higher at the aggregate level, and 1.5 (95% CI 0.68-453 2.20) beats per minute higher 22 hours after vaccination when we performed a pairwise 454 comparison. Previous studies have found that even small long-lasting increases in heart rate are associated with an increased risk of death.<sup>33, 34</sup> However, we found that the increases in heart rate 455 456 disappeared within six days after vaccination. We also found increases in the heart rate 457 variability-based stress measure. Some details are available on how the Garmin stress measure is

458 calculated,<sup>35, 36</sup> but the exact algorithm is proprietary and is not fully disclosed. Although the
459 stress measures returned to baseline within six days after vaccination, the clinical significance of
460 the short-term increases in the stress measure is unknown.

461 Our analysis has several limitations. First, we considered only BNT162b2 (Pfizer-462 BioNTech) mRNA vaccines. Second, median cohort age was greater than the median age in Israel, reflecting the fact that older individuals are more likely to receive both influenza 463 464 vaccination and a COVID-19 booster shot than younger individuals. It is possible that younger 465 individuals might have a different side effects profile than found in our cohorts. Third, the 466 Garmin smartwatches are not medical-grade wearable devices, although previous studies have demonstrated the accuracy of smartwatches in measuring heart rates<sup>37, 38</sup> and our analysis 467 468 considers relative heart rate values pre- and post-vaccination rather than absolute heart rate 469 values.

470 Our analysis demonstrates the power of examining patient data from multiple sources. 471 Although more individuals experienced side effects after COVID-19 vaccination than after 472 influenza vaccination, as reflected both in patient self-reports and in smartwatch data, the 473 differences in examined side effects detected by the smartwatches were small, the differences 474 disappeared by three days after vaccination, and heart measures returned to their pre-vaccination 475 baseline within six days after vaccination. Moreover, no statistically significant increase in the 476 risk of adverse events, as reflected in EHRs, was associated with COVID-19 vaccination. Taken 477 together, these findings support the safety of the first and second BNT162b2 (Pfizer-BioNTech) 478 mRNA COVID-19 booster shots.

479

480

## 481 Acknowledgments

- 482 This work was supported by the European Research Council, project #949850, and a Koret483 Foundation gift for Smart Cities and Digital Living.
- 484

# 485 Authors' contributions

- 486 Conception and design: DY, MY, ES and MLB. Collection and assembly of data: DY, MY, YL,
- 487 and ES had access to the raw data and were responsible for verifying the data. Analysis and
- 488 interpretation of the data: MY, DY, ES, YL, GQ, and MLB. Statistical analysis: MY, DY, ES
- 489 and MLB. Drafting the article: MY, DY, ES, GQ and MLB. Critical revision of the article for
- 490 important intellectual content: MY, DY, ES, GQ, ND and MLB. Final approval of the article: All
- 491 authors. Obtaining funding: DY, ES, and MLB.

## 492 **Declaration of Interests**

- 493 All authors declare no competing interests.
- 494
- 495 Data sharing statements According to this study's MHS's Helsinki and data utilization
- 496 committees' guidelines, no patient-level data is to be shared outside the permitted researchers.
- 497 Statistical analysis code will be available upon publication.

#### 498 **References**

- Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol*. Aug 2020;35(8):775-779.
- Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of
  vaccine acceptance rates. *Vaccines (Basel)*. Feb 16 2021;9(2)
- Johns Hopkins University Coronavirus Resource Center. Understanding vaccination
   progress. <u>https://coronavirus.jhu.edu/vaccines/international</u>
- Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat Med.*Aug 2021;27(8):1338-1339.
- 507 5. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. *Public Health*. May 2021;194:245-251.
- 509 6. International Federation of Pharmaceutical Manufacturers and Associations. Influenza.
   510 <u>https://ifpma.org/areas-of-work/improving-health-security/influenza/</u>
- 511 7. Bloomberg News. More than 12.7 billion shots given: COVID tracker.
   512 <u>https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/</u>
- 5138.Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to514identify atrial fibrillation. N Engl J Med. Nov 14 2019;381(20):1909-1917.
- Alavi A, Bogu GK, Wang M, et al. Real-time alerting system for COVID-19 and other
  stress events using wearable data. *Nat Med.* Jan 2022;28(1):175-184.
- 517 10. Mishra T, Wang M, Metwally AA, et al. Pre-symptomatic detection of COVID-19 from
  518 smartwatch data. *Nat Biomed Eng.* Dec 2020;4(12):1208-1220.
- 519 11. Zhu T, Watkinson P, Clifton DA. Smartwatch data help detect COVID-19. *Nat Biomed* 520 *Eng.* Dec 2020;4(12):1125-1127.
- 521 12. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based
   522 COVID-19 vaccines. *JAMA*. Jun 1 2021;325(21):2201-2202.
- Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and
   reactogenicity of COVID-19 vaccines: a vaccine recipient survey. *Life (Basel)*. Mar 17
   2021;11(3)
- 526 14. Gepner Y, Mofaz M, Oved S, et al. Utilizing wearable sensors for continuous and highly 527 sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine. *Commun* 528 *Med.* 2022;2(1):27.

- 529 15. Mofaz M, Yechezkel M, Guan G, et al. Self-reported and physiological reactions to the
  530 third BNT162b2 mRNA COVID-19 (booster) vaccine dose. *Emerg Infect Dis*.
  531 2022;28(7):1375-1383.
- 532 16. Yechezkel M, Mofaz M, Painsky A, et al. Safety of the fourth COVID-19 BNT162b2
  533 mRNA (second booster) vaccine: a prospective and retrospective cohort study. *Lancet*534 *Respir Med.* Feb 2023;11(2):139-150.
- 535 17. Guan G, Mofaz M, Qian G, et al. Higher sensitivity monitoring of reactions to COVID-19
  536 vaccination using smartwatches. *NPJ Digit Med.* Sep 9 2022;5(1):140.
- 537 18. Quer G, Gadaleta M, Radin JM, et al. Inter-individual variation in objective measure of
   538 reactogenicity following COVID-19 vaccination via smartwatches and fitness bands. *NPJ* 539 *Digit Med.* Apr 19 2022;5(1):49.
- 540 19. Oved S, Mofaz M, Lan A, et al. Differential effects of COVID-19 lockdowns on well541 being: interaction between age, gender and chronotype. *J R Soc Interface*. Jun
  542 2021;18(179):20210078.
- 543 20. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA
  544 Covid-19 vaccine. *N Engl J Med.* Dec 31 2020;383(27):2603-2615.
- 545 21. Garmin Support Center. What is the stress level feature on my Garmin watch? Jul 27, 2021.
   546 Accessed Jul 27, 2021. <u>https://support.garmin.com/en-</u>
   547 US/?faq=WT9BmhjacO4ZpxbCc0EKn9
- 548 22. Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and heart rate variability: a metaanalysis and review of the literature. *Psychiatry Investig*. Mar 2018;15(3):235-245.
- Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for finegrained stress level assessment. *Comput Methods Programs Biomed*. Sep 2017;148:71-80.
- 552 24. Centers for Disease Control and Prevention. Possible side effects after getting a COVID-19
   553 vaccine. Accessed May 9, 2022. <u>https://www.cdc.gov/coronavirus/2019-</u>
   554 <u>ncov/vaccines/expect/after.html</u>
- 555 25. Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 vaccine
   556 overview and safety. Accessed Jul 14, 2021. <u>https://www.cdc.gov/coronavirus/2019-</u>
   557 ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
- Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19
  vaccine in a nationwide setting. *N Engl J Med.* Sep 16 2021;385(12):1078-1090.
- Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac
  arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med.*Feb 2022;28(2):410-422.

- Searching
  Searching
  Yamin D, Yechezkel M, Arbel R, et al. Safety of monovalent and bivalent BNT162b2
  mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale,
  retrospective, self-controlled case series study. *Lancet Infect Dis.* Jun 20 2023;Epub ahead
  of print
- 567 29. Israeli Ministry of Health. Coronavirus (COVID-19) vaccines guidelines. Jan 1, 2023 (in Hebrew). Accessed Jan 17, 2023.
- 569 <u>https://www.health.gov.il/UnitsOffice/HD/PH/epidemiology/td/docs/365\_Corona.pdf</u>
- 570 30. Rothman KJ. *Epidemiology* : An Introduction. 2nd ed. Oxford University Press; 2012.
- 571 31. Worldometer. Israel Population. Accessed 2 May, 2023.
   572 <u>https://www.worldometers.info/world-population/israel-population/</u>
- 573 32. Hu C, Wei KC, Wang WH, Chang YC, Huang YT. Association of influenza vaccination
  574 with risk of Bell palsy among older adults in Taiwan. *JAMA Otolaryngol Head Neck Surg*.
  575 Jun 22 2023;
- S76 33. Chen XJ, Barywani SB, Hansson PO, et al. Impact of changes in heart rate with age on allcause death and cardiovascular events in 50-year-old men from the general population.
  S78 Open Heart. 2019;6(1):e000856.
- S79 34. Raisi-Estabragh Z, Cooper J, Judge R, et al. Age, sex and disease-specific associations
  between resting heart rate and cardiovascular mortality in the UK BIOBANK. *PLoS One*.
  2020;15(5):e0233898.
- 582 35. Firstbeat Technologies Ltd. Stress and recovery analysis method based on 24-hour heart 783 rate variability. Accessed May 24, 2023.
   584 <u>https://assets.firstbeat.com/firstbeat/uploads/2015/11/Stress-and-</u> 785 recovery whitepaper 20145.pdf
- 586 36. Google Patents. Procedure for detection of stress by segmentation and analyzing a heart
  587 beat signal. Patent number US20050256414A1. Accessed May 24, 2023.
  588 <u>https://patents.google.com/patent/US20050256414A1/en</u>
- 589 37. Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in
  590 wearable optical heart rate sensors. *NPJ Digit Med.* 2020;3:18.
- 38. Reddy RK, Pooni R, Zaharieva DP, et al. Accuracy of wrist-worn activity monitors during
  common daily physical activities and types of structured exercise: evaluation study. *JMIR Mhealth Uhealth*. Dec 10 2018;6(12):e10338.
- 594

# Table 1. Description of cohort participants and self-reported reaction severity after COVID-19 booster vaccination and influenza vaccination for individuals receiving both vaccines

		<b>Prospective Cohort</b>		Retrospective cohort
	COVID-19		COVID-19 and	COVID-19 and
	Vaccine	Influenza Vaccine	Influenza Vaccine	Influenza Vaccine
Total (%)	1905	899	689	31,297
	(100%)	(100%)	(100%)	(100%)
Sex				
Female (%)	964	460	355	16,956
	(50.6%)	(51.2%)	(51.5%)	(54.2%)
Male (%)	940	439	334	14,341
	(49.4%)	(48.8%)	(48.5%)	(45.8%)
Age (years)				
Mean	49.4	53	55.35	55.89
Std	15.50	15.19	14.71	19.05
Range	19-85	20 - 85	20 - 85	12-103
Median	52	55	58	59
Age range				
12-55 (%)	1116	456	293	13,609
	(58.6%)	(50.7%)	(42.5%)	(43.5%)
>55 (%)	789	443	396	17,688
	(41.4%)	(49.3%)	(57.5%)	(56.5%)
Underlying medical condition				
Yes (%)	765	441	357	14,347
	(40.2%)	(49.1%)	(51.8%)	(45.8%)
No (%)	1092	427	305	16,950
	(57.3%)	(47.5%)	(44.3%)	(54.2%)
Not reported	48	31	27	
	(2.5%)	(3.4%)	(3.9%)	NA
BMI				
≥30	413	212	177	5,069
	(21.7%)	(23.6%)	(25.7%)	(16.2%)
<30	1485	684	509	10,971
	(78.0%)	(76.1%)	(73.9%)	(35.1%)
Not reported	7 (0.3%)	(0.3%)	$\frac{3}{(0.4\%)}$	15,257
Population sector	(0.370)	(0.370)	(0.470)	(48.770)
General Jewish	18/18	878	671	20 //3
	(97.0%)	(97.7%)	(97.4%)	(94.1%)
Ultra-Orthodox Jewish	38	15	12	1.006
	(2.0%)	(1.6%)	(1.7%)	(3.2%)
Arab	19	6	6	847
	(1.0%)	(0.7%)	(0.9%)	(2.7%)

# Table 2. Adverse-events noted in the electronic health record during the 28-day period before and after each vaccination for the retrospective cohort

		COV	ID-19 Va	ccine	Influenza Vaccine				
	Cohort <sup>*</sup>	Event before <sup>**</sup>	Event after <sup>**</sup>	<b>Risk difference<sup>†</sup></b>	Cohort	Event before <sup>**</sup>	Event after <sup>**</sup>	<b>Risk difference</b> <sup>†</sup>	
Event	No. of persons	No. of events	No. of events	No. of events/ 10,000 persons	No. of persons	No. of events	No. of events	No. of events/ 10,000 persons	
Non-COVID-19 or -influenza hospitalizations	31,286	51	37	-4.5 (-10.2 – 1.3)	31,287	32	30	-0.6 (-5.8 - 4.2)	
Adverse events									
Acute kidney injury	31,212	7	7	0.0(-2.2-2.2)	31,193	13	8	-1.6 (-4.5 – 1.3)	
Anemia	29,636 165 118 -15.9 (-27.04.7) 29,230		29,230	151	155	1.4 (-10.3 – 13.0)			
Appendicitis	31,261	5	3	-0.6(-2.6-1.0)	31,257	8	8 4 -1.3		
Arrhythmia	30,189 91 69 -7.3 (-15.6 - 1.0)		-7.3 (-15.6 - 1.0)	30,037	73	76	-1.0 (-6.7 – 9.0)		
Arthritis or arthropathy	31,060	20	9	-3.5 (-7.1 - 0.0)	31,038	19	24	1.6 (-2.6 - 5.8)	
Bell's palsy	31,229	6	3	-1.0 (-2.9 - 1.0)	31,220	0	4	1.3 (0.3 – 2.6)	
Cerebral venous sinus thrombosis	31,287	0	1	0.3 (0.0 - 1.0)	31,286	0	0		
Deep vein thrombosis	31,158	8	7	-0.3 (-2.9 – 2.2)	31,151	14	16	0.6(-2.9-4.2)	
Guillain-Barré syndrome	31,283	0	0		31,283	0	1	0.3(0.0-1.0)	
Heart failure	31,004	37	19	-5.8 (-10.6 - 1.3)	30,939	20	22	0.6(-3.6-4.8)	
Herpes simplex virus infection	31,131	22	15	-2.2 (-6.1 - 1.6)	31,109	22	16	-1.9 (-5.8 - 1.9)	
Herpes zoster virus infection	31,046	31	18	-4.2(-8.7-0.0)	30,965	35	17	-5.8 (-10.31.3)	
Intracranial hemorrhage	31,253	3	3	-0.0(-1.6-1.6)	31,243	4	4	0.0 (-1.9 - 1.6)	
Ischemic stroke	31,009	31	15	-5.2 (-9.4 - 1.0)	30,955	10	18	2.6(-0.6-5.8)	

	COVID-19 Vaccine					Influenza Vaccine			
	Cohort <sup>*</sup>	Event before <sup>**</sup>	Event after <sup>**</sup>	<b>Risk difference</b> <sup>†</sup>	Cohort	Event before <sup>**</sup>	Event after <sup>**</sup>	<b>Risk difference</b> <sup>†</sup>	
Event	No. of persons	No. of events	No. of events	No. of events/ 10,000 persons	No. of persons	No. of events	No. of events	No. of events/ 10,000 persons	
Lymphadenopathy	31,034	25	39	4.5 (-0.6 - 9.7)	31,004	36	24	-3.9 (-8.7 – 1.0)	
Lymphopenia	31,287	0	0		31,287	0	0		
Myocardial infarction	31,169	15	13	-0.6 (-3.8 - 2.6)	31,141	9	14	1.6 (-1.3 – 4.8)	
Myocarditis	31,282	1	1	-0.0(-1.0-1.0)	31,278	1	0	-0.3(1.0-0.0)	
Neutropenia	31,210	13	11	-0.6(-3.8-2.6)	31,193	14	7	-2.2(-5.1-0.6)	
Other thrombosis	31,257	5	3	-0.6(-2.6-1.0)	31,256	3	5	0.6(-1.0-2.6)	
Paresthesia	30,752	77	51	-8.5 (-15.61.3)	30,639	68	67	-0.3 (-7.8 - 7.2)	
Pericarditis	31,264	1	4	1.0 (-0.3 – 2.6)	31,257	2	1	-0.3 (-1.3 - 0.6)	
Pulmonary embolus	31,227	3	0	-1.0(-2.2-0.0)	31,217	2	5	1.0(-0.6-2.6)	
Seizures	31,262	5	5	0.0 (-1.9 - 1.9)	31,244	1	2	0.3(-0.6-1.6)	
Syncope	30,989	39	39	0.0 (-5.5 - 5.5)	30,928	49	36	-4.2 (-10.0 - 1.6)	
Thrombocytopenia	31,205	12	10	-0.6(-3.5-2.2)	31,195	5	11	1.9(-0.6-4.5)	
Uveitis	31,231	5	2	-1.0(-2.6-0.6)	31,224	5	4	-0.3 (-2.2 - 1.6)	
Vertigo	29,874	182	145	-12.4 (-24.40.7)	29,540	158	144	-4.7 (-16.2 - 6.8)	

600 <sup>\*</sup>Individuals without previous diagnosis of the event before vaccination.

601 \*\*28-day period before vaccination and after vaccination.

<sup>602</sup> <sup>†</sup>The risk difference and confidence interval were estimated for each individual in a paired fashion with the use of a percentile bootstrap method

603 with 10,000 repetitions.



- **Figure 1.** Reported symptoms following COVID-19 and influenza vaccination. Error bars represent 95% confidence intervals based on a
- 607 binomial distribution.



Figure 2. Mean difference in heart rate (in beats per minute) and stress measure (in points) between the post-vaccination and baseline periods after COVID-19 and influenza vaccinations. Shaded regions represent 95% confidence intervals.



618 619

Figure 3. Paired analysis: daily mean changes in the smartwatch indicators for heart rate and the stress measure. For each participant, this was calculated as the mean change in the indicator (either heart rate or the stress measure) associated with COVID-19 vaccination compared to an individual's baseline minus the mean change in the indicator associated with influenza vaccination. Error bars represent 623 95% confidence intervals.

625 626	Supplementary Materials for:	ana, data from								
020	notions solf reporting smortwatches and electronic health records									
627 628 629 630	Matan Yechezkel, MS <sup>1</sup> , Gary Qian, MS <sup>2</sup> , Yosi Levi, MS <sup>1</sup> , Nadav Davidovitch, PhD <sup>3</sup> , Erez Yamin, PhD <sup>1,5*</sup> , Margaret L. Brandeau, PhD <sup>2*</sup> <sup>1</sup> Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel	Shmueli, PhD <sup>1,4*</sup> , Dan								
631	<sup>2</sup> Department of Management Science and Engineering, Stanford University, Stanford, California, United States of									
632	America									
633	<sup>3</sup> School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, B	Beersheva 84105, Israel								
634	<sup>4</sup> MIT Media Lab, Cambridge, MA, USA.									
635	<sup>5</sup> Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.									
636	*Contributed equally									
637	Address correspondence to: Matan Yechezkel, matany92@gmail.com									
638										
639 640 641 642 643	Keywords: COVID-19 vaccine, COVID-19 booster vaccine, BNT162b2 wearable sensors, influenza vaccine, seasonal influenza, vaccine reactions Table of Contents Appendix A – Study protocol	2, adverse effects,								
644	Prospective part	2								
645	Retrospective part	6								
646	Appendix B – Data collection platform and data access	9								
647	1.1 Architecture	9								
648	1.2 The PerMed Dashboard									
649	1.3 The Type of Data Collected and data access									
650	Appendix C – Prospective study participants' adherence	10								
651	Appendix D – Study design scheme	11								
652	Appendix E – Additional results									
653	References	14								
654 655										

# 656 Appendix A – Study protocol

## 657 **Prospective part**

658

## 659 Study Design

In this study we will analyze data that were already collected and will be collected as part of the PerMed study <sup>1</sup>. Participants in the PerMed study are recruited for a period of two years, during which they are equipped with a Garmin Vivosmart 4 smartwatches and are asked to wear them as much as they could. In addition, participants install two applications on their mobile phones: an application that passively collects data from the smartwatch and a dedicated mobile application which allows participants to fill a daily questionnaire and to report their vaccine date and specific hour. In this study, we will consider for each participant, the 7-days period prior to any vaccination dose as the baseline period.

667

# 668 Participants

669 The inclusion criteria for the PerMed study includes those aged > 18 years. Individuals who are not eligible to give 670 and sign a consent form of their free are excluded. In this study, we will analyze the data of participants aged 18 671 years and above, who reported receiving at least one dose of the BNT162b2 mRNA COVID-19 booster vaccine or 672 seasonal influenza vaccine after joining the PerMed study. To recruit participants and ensure they complete all the 673 study's requirements, we will hire a professional survey company. Potential participants will be recruited through 674 advertisements in social media, online banners, and word-of-mouth. The survey company is responsible for 675 guaranteeing the participants meet the study's requirements, in particular, that the questionnaires are filled daily, 676 ensuring the smartwatches are charged constantly and worn properly, and assisting participants resolve technical 677 problems.

678

# 679 Study procedures

Before participation in the study, all participants will be advised orally and in writing about the nature of the experiments and give written, informed consent. At this time, participants will be asked to complete an enrollment questionnaire that includes demographic information and health status. In addition, participants will be asked to install two applications on their mobile phones: an application that passively collects data from the smartwatch and the PerMed application, which allows participants to fill in the daily questionnaires. Participants will be given instructions regarding the self-reported symptoms questionnaires and how to operate the smartwatch, which they will wear as much as they can.

687

# 688 Enrollment questionnaire

All participants will fill a one-time enrollment questionnaire that includes demographic questions and questions about the participant's health condition in general. Specifically, the questionnaire will include the following: age, gender, height, weight and underlying medical conditions (Listed in Table 1, main text). Other questions such as name, address, phone and email will be recorded and used by the survey company to contact the participants. The answers will be filled-in directly by the survey company to the study's secured dashboard.

694

# 695 Monitoring device

Participants will be equipped with Garmin Vivosmart 4 smart fitness trackers. Among other features, the smartwatch
 provides all-day heart rate and heart rate variability and during-night blood oxygen saturation level tracking
 capabilities<sup>2</sup>.

The optical wrist heart rate (HR) monitor of the smartwatch is designed to continuously monitor a user's heart rate. The frequency at which heart rate is measured varies and may depend on the level of activity of the user: when the user starts an activity, the optical HR monitor's measurement frequency increases.

703

Since heart rate variability (HRV) is not easily accessible through Garmin's application programming interface (API), we use Garmin's stress level instead, which is calculated based on HRV. Specifically, the device uses heart rate data to determine the interval between each heartbeat. The variable length of time between each heartbeat is regulated by the body's autonomic nervous system. Less variability between beats correlates with higher stress levels, whereas an increase in variability indicates less stress<sup>3</sup>. A similar relationship between HRV and stress was also seen in <sup>4,5</sup>.

710

711 The Pulse Ox monitor of the smartwatch uses a combination of red and infrared lights with sensors on the back of 712 the device to estimate the percentage of oxygenated blood (peripheral oxygen saturation, SpO2%). The Pulse Ox 713 monitor is activated each day at a fixed time for a period of four hours (the default is 2AM-6AM). 714

Examining the data collected in our study, we identified an HR sample roughly every 15 seconds, an HRV sample
every 180 seconds, and an SpO2 sample every 60 seconds.

718 While the Garmin smartwatch provides state-of-the-art wrist monitoring, it is not a medical-grade device, and some 719 readings may be inaccurate under certain circumstances, depending on factors such as the fit of the device and the

- 720 type and intensity of the activity undertaken by a participant  $^{6-8}$ .
- 721

## 722 Vaccination questionnaire

723 The vaccination questionnaire we will use includes the following question:

724

COVID-19 vaccination – date, time and dose number. [note, this is for validation as vaccination data are reported in the EMR]

- 725
- 726
- 727
- 728
- 729
- 730
- 731
- 732

# 733 Daily questionnaires

All participants will complete the daily self-reported questionnaire in a dedicated application (the PerMed mobile application). The daily questionnaire we will use includes the following questions:

How is your mood today? • Awful (-2)• Bad (-1)• OK (0)• Good (1)• Excellent (2)

How would you describe the level of your stress during the last day?• Very Low (-2)• Low (-1)• Medium (0)• High (1)• Very high (2)

How would you define your last night sleep quality?• Awful (-2)• Bad (-1)• OK (0)• Good (1)• Excellent (2)

Try to remember how many minutes of sports activity you performed on the last day?

Have you experienced one or more of the following symptoms in the last 24 hours?• My general feeling is good, and I have no symptoms• Heat measured above 37.5• Cough• Sore throat• Runny nose• Headache• Shortness of breath• Muscle aches• Weakness / fatigue• Diarrhea• Nausea / vomiting• Chills• Confusion• Loss of sense of taste / smell• Another symptom.

- 736
- 737
- 738

## 739 Data Storage

740 Data collected from the mobile phone application and from the smartwatches will be stored on a secure server 741 within Tel Aviv University facilities. The server runs a CentOS operating system and is located in Software 742 Engineering Building at Tel Aviv University. This server is protected behind the university's firewall and is not 743 connected to external networks. In addition, a secure connection through an SSL protocol and a trusted certificate

- will be obtained for the transfer of information from the mobile phone application into the secured server.
- 745

Access will be restricted to investigators in the study. The information from the mobile application will be stored in

a structured manner on the secured server without any explicitly identifying information (name, ID number, email).

- Each participant will be assigned a coded participant number that will be used to identify the subject in the database.
- The code with the identified information will be stored in an encrypted form on a separate secured server that only
- the research manager will have access to. Access to all servers is restricted with username and password.
- 751

All (non-digital) questionnaires and signed informed consent documents will be stored in a secured cabinet in Tel Aviv University, to which only the research manager and the principal investigators will have access. No data collected as part of the study will be added to individuals' medical charts.

755

# 756 Data processing

We will perform several preprocessing steps. Concerning the daily questionnaires, in cases where participants will fill in the daily questionnaire more than once on a given day, only the last entry for that day will be considered, as it is reasoned that the last one likely best represented the entire day. Self-reported symptoms that are entered as the free text will be manually categorized. With regard to the smartwatch physiological indicators, data will first be aggregated per hour (by taking the mean value). Then, to impute missing values, we will perform a linear interpolation. Finally, data will be smoothed by calculating the moving average value using a five-hour sliding window.

764

771

# 765 Data Analysis and inclusion criteria

The questionnaire data will be preprocessed by manually categorizing any self-reported symptom entered as free text. If participants filled out the questionnaire more than once in one day, the last entry from that day was used in the analysis as it is likely more representative of the past day. Smartwatch data will be preprocessed as follows. First, we will compute the mean value of each hour of data. We will then perform a linear interpolation to impute missing hourly means. Lastly, we will smooth the data by calculating the five-hour moving average.

For each participant and each of the vaccines, we define the 7-day period prior to vaccination as the baseline period. For the analyses involving self-reported questionnaires, we will include participants who submitted at least one questionnaire during the baseline period and at least one questionnaire during the seven days post-vaccination. The two questionnaires are required to understand the appearance of new reactions following vaccination. For the

analyses involving smartwatch indicators, we will include participants who had at least one overlapping period of
data (i.e., same day of the week and same hour during the day) during their baseline and post vaccination periods.
The overlapping periods are required for computing the change in indicator values between the baseline and postvaccination periods.

781 To compare the changes in specific smartwatch indicators (heart rate, HRV-based stress, resting heart rate, and step 782 counts) over the 0-42 days post vaccination, with those of the baseline period, we will perform the following steps. 783 First, for each participant and each hour during the seven days post-vaccination, we will calculat the difference 784 between that hour's indicator value and that of the corresponding hour in the baseline period (keeping the same day 785 of the week and same hour during the day). Then, we will aggregate each hour's differences over all participants to 786 calculate a mean difference and the associated 95% confidence interval, which is analogous to a one-sided t-test 787 with a significance level of 0.05. To determine the statistical significance of daily differences between the baseline 788 and post vaccination period, we will calculate the mean daily difference for each participant and then used a one-789 sample t-test for each day. To compare the difference of physiological changes between COVID-19 vaccination and 790 seasonal influenza vaccination among individuals who received both vaccines. For each participant, we will first 791 calculate the daily mean changes in heart rate between the post-vaccination period and the baseline period. We will 792 do this separately for the mRNA COVID-19 booster vaccine and the seasonal influenza vaccine. Then we will 793 calculate the difference between these two mean values for each participant and each of the 7 days after inoculation. 794 This is equivalent to a two-sided Welch's t-test, which does not assume equal population variance. 795

To understand the extent of new reactions, post vaccination, we will first note any pre-existing signs and symptoms reported in the last completed questionnaire during the baseline period. Next, we will calculate the percentage of participants who reported new (i.e., not pre-existing) systemic reactions in the 7-day period after vaccination from the following list: fatigue, headache, muscle pain, cold, fever, sore throat, cough, chills, vomiting or nausea, diarrhoea, dyspnoea, confusion, loss of taste and smell, Shortness of breath. Participants could also report any other symptoms using free text. For each reaction we use a binomial distribution to determine a 95% confidence interval.

802

780

# 803 Potential Risks & Risk management

804 No specific risks arising from the smartwatches are expected, as the device is already commercialized with no 805 known adverse reactions. The main risk in this study is the leakage of private data which we intend to manage as we 806 describe in the following section.

807

# 808 Privacy/Confidentiality

Results from this study will be handled at an aggregated level. Individual data records will remain confidential and will not be published or shared with any third party. Signed and dated informed consent forms, as well as data recording sheets (e.g., case report forms) will be stored in locked cabinets during the study and following its completion. A file containing the personal details of the participants will be coded to help preserve confidentiality and will be separated from all other data collected throughout the study. This file will be kept by the principal investigator. Data will be stored on computers in password-protected files.

815 The data obtained from the smartwatch used in this study will be linked to a coded participant number. The 816 smartwatch does not include a GPS. The data collected by the PerMed application will arrive directly to PerMed 817 back-end servers and will be stored securely.

- 818
- 819

#### 820 **Retrospective part**

#### 821 Description of the data

822 Data will be extracted from the Maccabi Healthcare Services (MHS) database. MHS is a nationwide health plan 823 (payer-provider) representing a quarter of the population in Israel. The MHS database contains longitudinal data on 824 a stable population of 2.2 million people since 1993 (with <1%/year moving out). Data are automatically collected 825 and includes comprehensive laboratory data from a single central lab, full pharmacy prescription and purchase data, 826 and extensive demographic data on each patient. MHS uses the International Classification of Diseases, Ninth 827 Revision, Clinical Modification (ICD-9-CM) coding systems as well as self-developed coding systems to provide 828 more granular diagnostic information beyond the ICD codes. Medications are coded according to the Israeli coding 829 system with translations to anatomical therapeutic chemical (ATC) classification system wherever available. 830 Procedures are coded using Current Procedural Terminology (CPT) codes. We will access to the following data for 831 each patient: 832

- $\geq$ Socio-demographics
- 833 Sex (binary) • 834 Age (year of birth) • 835 Socioeconomic status by address and according clinic when address is missing) (scale 1-20) • 836 Supplementary insurance status (type of insurance structured 1-5) 837 Country of birth (coalesced into regions when necessary) and immigration date • 838 Sector (clinic level data - Arab / Jewish/ ultra-orthodox Jewish) 839 Affiliation by district, sub-district (out of 2750 regions) 840 Comorbidities 841 Charlson co-morbidity index (scale) • 842 Chronic diseases (binary classification) 843 History of malignancies and active malignancy 844 Cardiovascular diseases (ischaemic heart disease, cerebrovascular disease/ all cardio 0 845 sub registries ). 846 Diabetes (taken from CRI registry) 0 847 Hypertension (taken from CRI registry) 0 848 Asthma 0 849 0 Chronic Lung Disease 850 Rheumatologic diseases 0 851 Chronic Kidney Disease 0 852 Immunocompromised Status 0 853
  - Chronic Liver Disease 0
  - Additional Chronic Diseases 0
  - Acute and Chronic Medications (group of medications)
- 856 Vaccination records 857

854

855

859

860

- $\triangleright$ Laboratory test results ( binary classification for existence of infectious diseases)
- 858 Prescription drugs ( { type, dosage number }
  - $\triangleright$ Hospitalization history ({ admission data, primary service, duration})
  - $\triangleright$ Outpatient history (admission data, primary service, ICD diagnosis code)
- 861  $\geq$ BMI ({date,value}}
- $\triangleright$ 862 Smoking status {date, yes/no} 863

#### 864 Data collection and storage

865 We will receive access to the data from the medical records of 250,000 random members of Maccabi and the 5,000 866 participants from the prospective cohort. MHS is a nationwide health plan (payer-provider) representing a quarter of 867 the population in Israel. The MHS database contains longitudinal data on a stable population of 2.2 million people 868 since 1993 (with <1%/year moving out). Data are automatically collected and includes comprehensive laboratory 869 data from a single central lab, full pharmacy prescription and purchase data, and extensive demographic data on 870 each patient. MHS uses the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-871 CM) coding systems as well as self-developed coding systems to provide more granular diagnostic information

- 872 beyond the ICD codes. Medications are coded according to the Israeli coding system with translations to anatomical
- 873 therapeutic chemical (ATC) classification system wherever available. Procedures are coded using Current
- 874 Procedural Terminology (CPT) codes.
- 875 As for the medical data, we will receive access to the EMR data after the following pseudonymisation 876 procedures:
  - 1. Healthcare identification number of the members will be coded.
  - 2. Only year of birth is provided
- 879 Free text is removed. This means any text that was types/recorded/scanned manually by healthcare 3. 880 staff, and is not structured in the electronic system. This includes any documented conversations 881 between healthcare staff and patient or summary of from meetings. 882
  - 4. No audio, photos including scanned text, or video contents are provided.
- 883 The address of the members is not detailed, and only the statistical area is provided (Israel is stratified 5. 884 into 2733 statistical areas with around 2500-5000 individuals per region).

885

893

877

878

886 The data access of the retrospective part will be conducted at the MHS. The data are coded, viewed, stored and 887 process only within the Maccabi research room. The researchers will connect to the research room via MD Clone 888 platform, which is approved by the Ministry of Health. The user connects through a secure connection using 889 Lightweight Directory Access Protocol and two factor authentication system.

#### 890 Potential adverse events

891 We will examine 28 potential adverse events (Table S1) that were previously investigated in the context of COVID-

19 vaccination <sup>9,10</sup> 892

893	Table S1. ICD-9 codes of the examined potential adverse events in the retrospective cohort						
	Event	ICD-9 Code					
	A outo kidnow injury	594 [5 0]*					

Acute kidney injury	584.[5-9] <sup>*</sup>
Anemia	$28[0,1,3,4,5]^*$
Appendicitis	$54[0-2]^*, 47^*$
Arrhythmia	427*, 426*
Arthritis or arthropathy	$713^{*}, 714.9^{*}, 716.[4-9]^{*}, 718.9, 719.[0,1,6,8,9]^{*}$
Bell's palsy	351.0 <sup>*</sup>
Cerebral venous sinus thrombosis	325
Deep vein thrombosis	451, 451.[1-9] <sup>*</sup> , 453.[1,4] <sup>*</sup> , 453.8[0,2,3,4,5,6,7,8,9], 671.[3,4] <sup>*</sup>
Guillain-Barré syndrome	357.0
Heart failure	$428^{*}$
Herpes simplex virus infection	$054^*$
Herpes zoster virus infection	053*
Intracranial hemorrhage	$43[0,1,2]^{*}$
Ischemic stroke	433, 433.[0,1,2,3,8,9], 433.[0,1,2,3,8,9]1, 434 <sup>*</sup> , 362.3[1-3], 436 <sup>*</sup>
Lymphadenopathy	$785.6^*, 683^*, 289.[2,3]^*$
Lymphopenia	288.5 <sup>*</sup>
Myocardial infarction	410*
Myocarditis	422 <sup>*</sup> , 429.0 <sup>*</sup> , 398.0 <sup>*</sup> , 391.2 <sup>*</sup>
Neutropenia	288.0, 288.0[0,3,4,9]
Other thrombosis	444 <sup>*</sup> , 557.[0,9] <sup>*</sup> , 557, 452 <sup>*</sup> , 453, 453.[0,1,2,3,4,9] <sup>*</sup> , 453.[7,8], 453.[7,8][2-9], 437.6 <sup>*</sup>
Paresthesia	782.0 <sup>*</sup>

Pericarditis	420 <sup>*</sup>
Pulmonary embolus	415.1 <sup>*</sup> , 673.[2,8] <sup>*</sup>
Seizures	345.[2,3]*, 780.3, 780.39
Syncope	780.2 <sup>*</sup> , 992.1 <sup>*</sup>
Thrombocytopenia	287.2 <sup>*</sup> , 287.3, 287.3[0,1,3,9], 287.5
Uveitis	360.12, 362.18, 363.0 <sup>*</sup> . 363.2[0,1,2], 363.1 <sup>*</sup> , 364.[0,1,2,3] <sup>*</sup> , 053.22, 054.44, 091.5 <sup>*</sup> , 098.41, 115.92
Vertigo	780.4 <sup>*</sup> , 78.81, 386.1[0,1,9], 386.2, 438.85

894

\*Any of the possible ICD-9 combinations with a match

#### 896 Appendix B – Data collection platform and data access

897

900

901

902

903

904

#### 898 Architecture

899 The data collection platform contains several components that interact with each other (see Figure 2):

- **The PerMed application** This application is installed on each participant's phone to collect sensors data and the self-reported daily questionnaires. It also handles the smartwatch pairing. The current version of the application supports both Android and iOS devices.
  - **The smartwatch** send the data to the Garmin Connect app on the smartphone, which then sends these data to Garmin's server.
- 905
   The smartwatch application This application (currently Garmin) receives information from the smartwatch via Bluetooth and transmits it to the company's server. In addition, it provides a convenient interface for displaying the participant's smartwatch information.
- 908
   The app server The webserver handles the database connectivity using REST API pages. It enables the server to authenticate users as they launch the application and write records to the database. A MySQL server stores the sensors' raw data and the answers to the daily questionnaires. At last, there is a batch processes running on the server that sends app notifications (daily reminder to fill the questionnaire).
- 913
   The dashboard server hosts the dashboard pages, which assist in monitoring the quality of the information and controlling the experiment. The dashboard has access to participant information and signals indicating whether questionnaires were completed and the smart watch was worn without seeing its content directly. A batch process is responsible for aggregating raw data for dashboard statistics.
- 917
   The smartwatch server A MySQL server stores the smartwatch data. A batch process is responsible for collecting the data from the Garmin server.



Figure S1. The high-level architecture of the PerMed's data collection platform.

#### 921 The PerMed Dashboard

922 Participants will be recruited by a qualified external recruitment team headed by Tel Aviv University 923 personal. The team receive limited information essential control the experiment. Thus, we developed a 924 dedicated dashboard for monitoring the quality of the information and control the experiment. This 925 dashboard aims to identify data collection issues such as participants who did not fill the daily 926 questionnaires or participants who did not charge the battery of their smartwatches. The dashboard also 927 helps us identify problems that were not related to participants' cooperation, such as bugs in the mobileapp. 928 This identification allow us to respond faster and provide timely solutions.

- 929 The Type of Data Collected and data access
- 930 Data collected by the platform arrive from four primary sources:
- 931 Enrolment questionnaire - data were collected from a one-time enrollment 932 questionnaire that includes basic personal characteristics such as socio-demographic 933 information (e.g., age, gender, height, weight), general habits, health status, and a short 934 Big Five personality questionnaire.
- 935 **Daily questionnaire** – consists of questions on 1) wellbeing, 2) general health condition, 936 3) symptoms observed, 4) test results to diagnose infectious diseases, 4) vaccination or 937 medicationconsumption (if relevant to the study question). 938
  - Smartphone sensor data consist of location, Wi-Fi, Bluetooth, screen, and activity.
  - Smartwatch data consist of heart rate data, accelerometer and gyroscope information and measures based on these data including active minutes, steps, distance, calories, and sleep level classification, including light, deep, REM, and awake periods.
- 942 The current research, aims to explore the safety of vaccination, is part of a larger study. Raw accelerometer
- 943 data, mobile activity and GPS locations are generally considered sensitive information. In accordance with the
- 944 data minimization principle, we did not extract these type of data for this vaccination safety research.
- 945

939

940

941

#### 946 Appendix C – Prospective study participants' adherence

947 We employed a professional survey company to recruit participants and ensure they adhere to the study 948 requirements. Participant recruitment was performed via advertisements on social media and word-of-mouth. Each 949 participant signed an informed consent form after receiving a comprehensive explanation on the study. Then, 950 participants completed a one-time enrollment questionnaire, were equipped with Garmin Vivosmart 4 smartwatches, and installed two applications on their mobile phones: (1) the PerMed application <sup>1,11,12</sup>, which collects daily self-951 952 reported questionnaires, and (2) an application that passively records smartwatch data. Participants were asked to 953 wear their smartwatches as much as possible. The survey company ensured that participants' questionnaires were 954 filled at least twice a week, that their smartwatches were charged and properly worn, and that any technical 955 problems with the mobile applications or smartwatch were resolved. Participants were monitored through the mobile 956 application and smartwatches for a period of at least 49 days, starting seven days before vaccination. Participants 957 also granted full access to their EMR data.

958

959 We implemented several preventive measures to minimize participant attrition and discomfort as a means to 960 improve the quality, continuity and reliability of the collected data. First, each day, participants who did not fill their 961 daily questionnaire by 7 pm received a reminder notification through the PerMed application. Second, we developed 962 a dedicated dashboard that allowed the survey company to identify participants who repeatedly neglected to 963 complete the daily questionnaire or did not wear their smartwatch for extended periods of time; these participants 964 were contacted by the survey company (either by text message or phone call) and encouraged to better adhere to the 965 study protocol. Third, to strengthen participants' engagement, a weekly personalized summary report was generated 966 for each participant, which was available inside the PerMed application. Similarly, a monthly newsletter with recent 967 findings from the study and useful tips regarding the smartwatch's capabilities was sent to the participants. At the 968 end of the study, participants will receive all personal insights that were obtained and can keep the smartwatch as a 969 gift.

- 970 971
- 972
- 973 Appendix D Study design scheme974
- 975



Figure S2. Trail profile. (A) prospective study, (B) retrospective study

# 976 **Table S2.** Number of prospective vaccine cohort observations<sup>\*</sup>

			smartwatch da vaccii	ta differences f nation	ollowing	Daily smarty	vatch data diffe	rences followin	g vaccination	Reported s	symptoms 7
		Heart Rate	(Smoothed)	Heart Rate (Smo	variability othed)	Heart Rate	(Smoothed)	Heart Rate (Smo	e Variability othed)	days fo vacci	llowing nation
Vaccine type	No. vaccines	No. obser- vations	No. paired observations	No. obser- vations	No. paired observations	No. obser- vations	No. paired observations	No. obser- vations	No. paired observations	No. obser- vations	No. paired observations
COVID-19 (3 <sup>rd</sup> and/or 4 <sup>th</sup> dose)	4334	1877	799	1845	779	1888	804	1858	784	2165	881
Influenza	2639	901	692	878	672	905	698	881	677	959	727
Number of participants vaccinated with both vaccines		5	77	5	44	5	62	5	49	6	21

 $\begin{array}{l} 977 \\ 978 \end{array}^{*} Observations represent time series data following vaccination. Paired observations are those for which the individual received both a COVID-19 vaccination (3<sup>rd</sup> or 4<sup>th</sup> dose) and an influenza vaccination. \end{array}$ 

# 979 Appendix E – Additional results

980



Influenza vaccine

Figure S1. Comparison of self-reported reaction severity for COVID-19 vaccination and influenza vaccination among 621 individuals receiving both vaccines: number and percent of individuals reporting various combinations of no reaction, mild reaction, and severe reaction to the COVID-19 vaccine and influenza vaccine

985

987	Refe	rences
988	1	Oved S, Mofaz M, Lan A, et al. Differential effects of COVID-19 lockdowns on well-being: interaction
989		between age, gender and chronotype. 2021 DOI:10.21203/RS.3.RS-137929/V1.
990	2	VÍVOSMART ® 4 Owner's Manual. 2018.
991	3	What Is the Stress Level Feature on My Garmin Watch?   Garmin Support. https://support.garmin.com/en-
992		US/?faq=WT9BmhjacO4ZpxbCc0EKn9 (accessed Aug 24, 2021).
993	4	Kim H-G, Cheon E-J, Bai D-S, Lee YH, Koo B-H. Stress and Heart Rate Variability: A Meta-Analysis and
994		Review of the Literature. Psychiatry Investigation 2018; 15: 235.
995	5	Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for fine-grained stress level
996		assessment. Computer Methods and Programs in Biomedicine 2017; 148: 71-80.
997	6	RK R, R P, DP Z, et al. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical
998		Activities and Types of Structured Exercise: Evaluation Study. JMIR mHealth and uHealth 2018; 6.
999		DOI:10.2196/10338.
1000	7	Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart
1001		rate sensors. npj Digital Medicine 2020 3:1 2020; 3: 1–9.
1002	8	Accuracy   Garmin. https://www.garmin.com/en-US/legal/atdisclaimer/ (accessed Aug 22, 2021).
1003	9	Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
1004		Nationwide Setting. New England Journal of Medicine 2021; 385: 1078–90.
1005	10	Yechezkel M, Mofaz M, Painsky A, et al. Safety of the fourth COVID-19 BNT162b2 mRNA (second
1006		booster) vaccine: a prospective and retrospective cohort study. Lancet Respir Med 2022; 0.
1007		DOI:10.1016/S2213-2600(22)00407-6.
1008	11	Mofaz M, Yechezkel M, Guan G, et al. Self-Reported and Physiologic Reactions to Third BNT162b2
1009		mRNA COVID-19 (Booster) Vaccine Dose. Emerging Infectious Diseases 2022; 28: 1375.
1010	12	Gepner Y, Mofaz M, Oved S, et al. Utilizing wearable sensors for continuous and highly-sensitive
1011		monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine. Communications Medicine 2022 2:1
1012		2022; <b>2</b> : 1–8.
1013		
1014		
1015		
1016		
1017		